Background Bivalirudin has been shown to be associated with less major bleeding than
heparin in patients undergoing percutaneous coronary intervention (PCI); but the …

Recent clinical trials have shown that while bivalirudin exhibits similar efficacy with heparin,
it offers several advantages over heparin, such as a better safety profile. We aimed to …

Aims The efficacy and safety of bivalirudin in patients undergoing percutaneous coronary
intervention (PCI) for treatment of acute coronary syndromes (ACS) remains controversial …

Background The comparative efficacy of various anticoagulation strategies has not been
clearly established in patients with acute myocardial infarction who are undergoing …

Objectives We aimed to perform a gender‐based meta‐analysis of the outcome of
bivalirudin versus heparin in patients undergoing percutaneous coronary interventions …

BACKGROUND: Bivalirudin is replacing heparin as the anticoagulant agent of choice for
elective percutaneous coronary intervention (PCI). This study aimed to assess the safety and …

In the absence of head-to-head clinical data, the objective of this study was to indirectly
compare the efficacy and safety of a bivalirudin-based anticoagulation strategy with that of …

This study sought to investigate the relative safety and efficacy of bivalirudin versus heparin
plus glycoprotein (GP) IIb/IIIa inhibitors in patients undergoing percutaneous coronary …

Background Despite several randomized controlled trials and meta-analyses, the ideal
anticoagulant for patients undergoing primary percutaneous coronary intervention (PCI) …

Introduction: Anticoagulant therapy is critical to prevent ischemic recurrences and
complications in acute coronary syndrome (ACS) patients undergoing percutaneous …